We examined six major drivers of aggressive disease – PTEN, MYC, RB1, TP53, AURKA, AR – by immunohistochemistry in a focused (N = 69) cohort predominantly consisting of intermediate risk prostate cancer. Here, TP53 is linked to prostate cancer.